Ironwood Pharma (IRWD) Misses Q1 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance
May 2, 2019 7:00 AM EDTIronwood launches as GI-focused healthcare company following separation of Cyclerion Therapeutics on April 1, 2019
First quarter 2019 revenue of $69 million driven primarily by LINZESS® (linaclotide) collaboration revenue; reiterates full year 2019 revenue guidance
LINZESS prescription demand grew 14% year-over-year in first quarter 2019
Late-stage GI pipeline continues to progress; IW-3718 is enrolling patients in phase III trials and MD-7246 phase II trial expected to initiate in May 2019
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
